7,700 Shares in Natera, Inc. (NASDAQ:NTRA) Bought by Black Swift Group LLC

Black Swift Group LLC bought a new position in shares of Natera, Inc. (NASDAQ:NTRA) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 7,700 shares of the medical research company’s stock, valued at approximately $1,219,000.

Other large investors have also added to or reduced their stakes in the company. Blue Trust Inc. boosted its holdings in Natera by 104.3% during the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after purchasing an additional 97 shares during the last quarter. Versant Capital Management Inc raised its position in Natera by 345.8% during the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock worth $34,000 after acquiring an additional 166 shares in the last quarter. Covestor Ltd raised its position in Natera by 34.3% during the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after acquiring an additional 95 shares in the last quarter. Principal Securities Inc. raised its position in Natera by 20.7% during the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock worth $54,000 after acquiring an additional 59 shares in the last quarter. Finally, True Wealth Design LLC bought a new stake in Natera during the third quarter worth $57,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on NTRA shares. Piper Sandler upped their price target on shares of Natera from $200.00 to $205.00 and gave the stock an “overweight” rating in a research report on Tuesday. StockNews.com lowered shares of Natera from a “hold” rating to a “sell” rating in a research report on Monday. Morgan Stanley upped their price target on shares of Natera from $176.00 to $185.00 and gave the stock an “overweight” rating in a research report on Wednesday. Guggenheim upped their price target on shares of Natera from $170.00 to $200.00 and gave the stock a “buy” rating in a research report on Friday, January 17th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $180.00 price target on shares of Natera in a research report on Wednesday, February 26th. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $173.56.

Insiders Place Their Bets

In related news, CFO Michael Burkes Brophy sold 43,502 shares of the firm’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $176.88, for a total value of $7,694,633.76. Following the completion of the transaction, the chief financial officer now owns 70,629 shares in the company, valued at $12,492,857.52. This trade represents a 38.12 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider John Fesko sold 663 shares of the firm’s stock in a transaction that occurred on Thursday, February 6th. The shares were sold at an average price of $177.77, for a total transaction of $117,861.51. Following the completion of the transaction, the insider now owns 156,044 shares of the company’s stock, valued at approximately $27,739,941.88. This trade represents a 0.42 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 208,299 shares of company stock worth $34,948,265 over the last ninety days. Corporate insiders own 7.60% of the company’s stock.

Natera Trading Up 3.9 %

Shares of Natera stock opened at $147.92 on Thursday. The company has a market capitalization of $19.53 billion, a price-to-earnings ratio of -84.05 and a beta of 1.66. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. Natera, Inc. has a 12-month low of $83.13 and a 12-month high of $183.00. The firm’s 50-day moving average price is $166.66 and its two-hundred day moving average price is $147.62.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.01. The firm had revenue of $476.10 million for the quarter, compared to the consensus estimate of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. On average, analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.